R-citalopram functionally antagonises escitalopram in vivo and in vitro: Evidence for kinetic interaction at the serotonin transporter

British Journal of Pharmacology

Volumn 142, Issue 1, 2004, Pages 172-180

  Stórustovu, Signe Í ^a   Sánchez, Connie ^a   Pörzgen, Peter ^a   Brennum, Lise T ^a   Larsen, Anna Kirstine ^a   Pulis, Monica ^a   Ebert, Bjarke ^a  

^a H LUNDBECK A S   (Denmark)

Author keywords

5 HTP; Behaviour; Citalopram; Escitalopram; Functional antagonism; In vivo binding; Kinetic interaction; Xenopus oocytes

Indexed keywords

CITALOPRAM; ESCITALOPRAM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG POTENTIATION; ELECTROPHYSIOLOGY; FEMALE; KINETICS; MALE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OOCYTE; PRIORITY JOURNAL; XENOPUS;

ANIMALS; CITALOPRAM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MICE; NERVE TISSUE PROTEINS; PROTEIN BINDING; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STEREOISOMERISM; XENOPUS LAEVIS;

EID: 2542612920     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0705738     Document Type: Article

References (27)

1. AMARA, S.G. & KUHAR, M.J. (1993). Neurotransmitter transporters: recent progress. Annu. Rev. Neurosci., 16, 73-93.
2. 3H]GBR 12935 binding in vivo in mouse brain: labelling of a piperazine acceptor site. Eur. J. Pharmacol., 144, 1-6.
3. ARTIGAS, F., PEREZ, V. & ALVAREZ, E. (1994). Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry, 51, 248-251.
4. 1A antagonists. Trends Neurosci., 19, 378-383.
5. 1A receptors induces rapid anti-depressant response. Neuropsychopharmacology, 16, 333-338.
6. BLIER, P. & DE MONTIGNY, C. (1994). Current advances and trends in the treatment of depression. Trends Pharmacol. Sci., 15, 220-226.
7. BRÄUNER-OSBORNE, H., EBERT, B., BRANN, M.R., FALCH, E. & KROGSGAARD-LARSEN, P. (1996). Functional partial agonism at cloned human muscarinic acetylcholine receptors. Eur. J. Pharmacol., 313, 145-150.
8. CHALON, S., TARKIAINEN, J., GARREAU, L., HALL, H., EMOND, P., VERCOUILLIE, J., FARDE, L., DASSE, P., VARNAS, K., BESNARD, J.C., HALLDIN, C. & GUILLOTEAU, D. (2003). Pharmacological characterization of N,N-dimethyl-2-(2-amino-4-methylphenyl thio)benzylamine as a ligand of the serotonin transporter with high affinity and selectivity. J. Pharmacol. Exp. Ther., 304, 81-87.
9. EBERT, B., MADSEN, U., LUND, T.M., LENZ, S.M. & KROGSGAARD-LARSEN, P. (1994). Molecular pharmacology of the AMPA agonist, (S)-2-amino-3-(3-hydroxy-5- phenyl4-isoxazolyl)propionic acid [(S)-APPA] and the AMPA antagonist, (R)-APPA. Neurochem. Int., 24, 507-515.
10. GADDUM, J.H. (1937). The quantitative effects of antagonistic drugs. J. Physiol. (Lond.), 89, 7P-9P.
11. HYTTEL, J., BØGESØ, K.P., PERREGAARD, J. & SÁNCHEZ, C. (1992). The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer. J. Neural Transm. Gen. Sect., 88, 157-160.
12. KUGELBERG, F.C., APELQVIST, G., CARLSSON, B., AHLNER, J. & BENGTSSON, F. (2001). In vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to rats. Br. J. Pharmacol., 132, 1683-1690.
13. 3H-MADAM binding to 5-hydroxytryptamine transporters in vitro and in vivo in mice; correlation with behavioural data. Br. J. Pharmacol., (in press).
14. LEPOLA, U.M., LOFT, H. & REINES, E.H. (2003). Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int. Clin. Psychopharmacol., 18, 211-217.
15. + channel determined by construction of multimeric cDNAs. Neuron, 9, 861-871.
16. MAGER, S., MIN, C., HENRY, D.J., CHAVKIN, C., HOFFMAN, B.J., DAVIDSON, N. & LESTER, H.A. (1994). Conducting states of a mammalian serotonin transporter. Neuron, 12, 845-859.
17. MONTGOMERY, S.A., LOFT, H., SÁNCHEZ, C., REINES, E.H. & PAPP, M. (2001). Escitalopram (S-enantiomer of citalopram): clinical efficacy and onset of action predicted from a rat model. Pharmacol. Toxicol., 88, 282-286.
18. MORTENSEN, O.V., KRISTENSEN, A.S., RUDNICK, G. & WIBORG, O. (1999). Molecular cloning, expression and characterization of a bovine serotonin transporter. Brain Res. Mol. Brain Res., 71, 120-126.
19. MØRK, A., KREILGAARD, M. & SÁNCHEZ, C. (2003). The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats. Neuropharmacology, 45, 167-173.
20. QUICK, M.W. (2002). Substrates regulate gamma-aminobutyric acid transporters in a syntaxin 1A-dependent manner. Proc. Natl. Acad. Sci. U.S.A., 99, 5686-5691.
21. RAMAMOORTHY, S. & BLAKELY, R.D. (2003). Phosphorylation and sequestration of serotonin transporters differentially modulated by psychostimulants. Science, 285, 763-766.
22. REINES, E.H. (2002). Escitalopram is efficacious and well tolerated in the treatment of depression in primary care. Eur. Neuropsychopharmcol., 12 (Suppl 3), S254.
23. SÁNCHEZ, C. (2003). R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model. Eur. J. Pharmacol., 464, 155-158.
24. SÁNCHEZ, C., BERGQVIST, P.B.F., BRENNUM, L.T., GUPTA, S., HOGG, S., LARSEN, A. & WIBORG, O. (2003). Escitalopram, the (5)-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive anti-depressant and anxiolytical activities. Psychopharmacology, 167, 353-362.
25. SMITH, P.K., KROHN, R.I., HERMANSON, G.T., MALLIA, A.K., GARTNER, F.H., PROVENZANO, M.D., FUJIMOTO, E.K., GOEKE, N.M., OLSON, B.J. & KLENK, D.C. (1985). Measurement of protein using bicinchoninic acid. Anal. Biochem., 150, 76-85.
26. SONDERS, M.S. & AMARA, S.G. (1996). Channels in transporters. Curr. Opin. Neurobiol., 6, 294-302.
27. WHITWORTH, T.L., HERNDON, L.C. & QUICK, M.W. (2002). Psychostimulants differentially regulate serotonin transporter expression in thalamocortical neurons. J. Neurosci., 22, RC192.